Sally J Bailey, MD
Allergy/Immunology · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 4 carriers
- Offices
- 3
- Since medical school
- 28 years
- Graduated 1998
Offices
3 locations · Allergy and Asthma Medical Group of the Bay Area Inc · Johns Hopkins University
Looking this up.
Hospitals listed: Johns Hopkins Bayview Medical Center. That is not proof they admit you there this week.
Plans that list them
10 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bailey’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Johns Hopkins Bayview Medical CenterBaltimore, MDAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Johns Hopkins Health System, which runs 6 hospitals in 3 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.39 (0.88 to 1.9) · 9,078 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.555, Oct 2024 – Sep 2025
See every measure and the patient survey for Johns Hopkins Bayview Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 3 better, 7 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.39 (0.88 to 1.9) · 9,078 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.555 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,296 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.86 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.64 (139.91 to 229.37) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.8 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.2 · 375 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 299 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 2,681 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 9,594 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.07 to 0.44) · 9,309 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.28 (2.43 to 6.14) · 1,719 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.94 (0.55 to 3.34) · 1,712 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.74 (1.11 to 14.38) · 658 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.62 (1.14 to 8.11) · 560 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.09 to 2.93) · 357 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 46 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.011 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.954 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.203 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.601 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 557 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -37.3 · 98 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 538 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -28.9 · 375 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 14.4 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.6 to 7.2) · 219 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (9.9 to 15.5) · 219 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 368 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.9 to 19) · 815 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1.1) · 807 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,071 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Drugs they prescribed that Part D paid
$44,710
Pharmacies billed $44,710 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 23) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
0 generic and 13 brand-name prescriptions · $44,710 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 12 | $41,896 | $3,491 |
Year by year
| 2024 | 23 | None | 0% (0) | 57% | $44,710 |
| 2023 | 13 | None | 0% (0) | None | $6,521 |
| 2022 | 25 | None | 0% (0) | None | $8,960 |
| 2021 | 22 | None | 0% (0) | 68% | $8,994 |
| 2020 | 33 | None | 0% (0) | 64% | $13,360 |
| 2019 | 12 | None | 0% (0) | 100% | $4,713 |
| 2018 | 16 | None | 0% (0) | 81% | $5,684 |
| 2014 | 13 | None | 0% (0) | None | $746 |
| 2013 | 11 | None | 0% (0) | None | $300 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2020: 1 drug
| Breo Ellipta | 14 | $9,173 | $655 |
Money from drug and device companies
$95,315 in 2025
| 2025 | 14 | 117 | $77,386 | $95,315 |
| 2024 | 16 | 117 | $70,399 | $82,688 |
| 2023 | 16 | 162 | $41,824 | $57,119 |
| 2022 | 13 | 120 | $26,590 | $36,869 |
| 2021 | 12 | 79 | $24,490 | $26,512 |
| 2020 | 9 | 63 | $22,500 | $24,608 |
| 2019 | 9 | 73 | $15,400 | $20,458 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $52,598 | 48 payments
|
| Optinose US | Xhance | $16,034 | 16 payments
|
| Novartis Pharmaceuticals | None | $8,266 | 11 payments
|
| ALK-Abello | Odactra | $7,115 | 14 payments
|
| kaleo | Auvi-Q | $4,464 | 6 payments
|
| GlaxoSmithKline | Nucala | $3,277 | 8 payments
|
See all 117 published payments
| Grifols USA | Meals · 2025-12-30 | Xembify | $34 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-19 | Dupixent | $2,932 |
| Incyte | Meals · 2025-12-18 | Opzelura | $22 |
| Regeneron Healthcare Solutions | Meals · 2025-12-10 | Dupixent | $119 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-09 | Fasenra | $16 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-09 | Dupixent | $2,399 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-09 | Dupixent | $5,597 |
| GlaxoSmithKline | Meals · 2025-12-08 | Trelegy Ellipta | $3 |
| Regeneron Healthcare Solutions | Travel · 2025-12-08 | Dupixent | $732 |
| GlaxoSmithKline | Meals · 2025-12-07 | Trelegy Ellipta | $18 |
| Regeneron Healthcare Solutions | Travel · 2025-12-07 | Dupixent | $0 |
| Regeneron Healthcare Solutions | Meals · 2025-12-07 | Dupixent | $98 |
| Regeneron Healthcare Solutions | Travel · 2025-12-06 | Dupixent | $264 |
| Regeneron Healthcare Solutions | Travel · 2025-12-06 | Dupixent | $294 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-05 | Dupixent | $5,597 |
| Regeneron Healthcare Solutions | Travel · 2025-12-05 | Dupixent | $760 |
| Regeneron Healthcare Solutions | Travel · 2025-12-05 | Dupixent | $553 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-05 | Dupixent | $2,932 |
| Regeneron Healthcare Solutions | Travel · 2025-12-05 | Dupixent | $614 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-12-05 | Dupixent | $2,932 |
| GlaxoSmithKline | Paid to speak or teach · 2025-12-04 | None | $1,300 |
| Regeneron Healthcare Solutions | Travel · 2025-12-04 | Dupixent | $484 |
| Regeneron Healthcare Solutions | Meals · 2025-12-04 | Dupixent | $125 |
| Regeneron Healthcare Solutions | Travel · 2025-12-04 | Dupixent | $726 |
| Regeneron Healthcare Solutions | Travel · 2025-12-03 | Dupixent | $264 |
| Regeneron Healthcare Solutions | Meals · 2025-12-03 | Dupixent | $27 |
| GlaxoSmithKline | Meals · 2025-11-19 | Nucala | $13 |
| Amgen | Meals · 2025-11-19 | Tezspire | $27 |
| GlaxoSmithKline | Travel · 2025-11-18 | None | $735 |
| Regeneron Healthcare Solutions | Travel · 2025-11-05 | Dupixent | $436 |
| GlaxoSmithKline | Paid to speak or teach · 2025-10-17 | None | $975 |
| Regeneron Healthcare Solutions | Travel · 2025-10-17 | Dupixent | $174 |
| Sanofi US Services | Meals · 2025-10-10 | Ayvakit | $55 |
| Novartis Pharmaceuticals | Meals · 2025-08-15 | None | $188 |
| Novartis Pharmaceuticals | Meals · 2025-08-15 | None | $36 |
| Novartis Pharmaceuticals | Consulting · 2025-08-15 | None | $6,550 |
| Novartis Pharmaceuticals | Travel · 2025-08-15 | None | $167 |
| Novartis Pharmaceuticals | Travel · 2025-08-15 | None | $297 |
| Novartis Pharmaceuticals | Travel · 2025-08-15 | None | $56 |
| Novartis Pharmaceuticals | Travel · 2025-08-14 | None | $488 |
| Novartis Pharmaceuticals | Travel · 2025-08-14 | None | $307 |
| Novartis Pharmaceuticals | Meals · 2025-08-14 | None | $122 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-07-01 | Dupixent | $3,465 |
| Regeneron Healthcare Solutions | Meals · 2025-06-27 | Dupixent | $109 |
| Greer Laboratories | Meals · 2025-06-27 | Oralair | $248 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-24 | Dupixent | $1,066 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-24 | Dupixent | $888 |
| Optinose US | Meals · 2025-06-17 | Xhance | $100 |
| Optinose US | Travel · 2025-06-17 | Xhance | $859 |
| Optinose US | Paid to speak or teach · 2025-06-17 | Xhance | $2,530 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-13 | None | $2,932 |
| Regeneron Healthcare Solutions | Meals · 2025-06-11 | None | $105 |
| ALK-Abello | Meals · 2025-06-05 | Timothy, Standardized | $85 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-06-04 | Dupixent | $1,866 |
| ALK-Abello | Meals · 2025-06-04 | Timothy, Standardized | $17 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $27 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $31 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $31 |
| ALK-Abello | Meals · 2025-06-03 | Odactra | $33 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $89 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $409 |
| ALK-Abello | Travel · 2025-06-03 | Odactra | $724 |
| ALK-Abello | Honoraria · 2025-06-03 | Odactra | $3,600 |
| Regeneron Healthcare Solutions | Meals · 2025-06-01 | Dupixent | $31 |
| GlaxoSmithKline | Meals · 2025-05-31 | Nucala | $107 |
| Novartis Pharmaceuticals | Meals · 2025-05-31 | None | $7 |
| Genzyme | Meals · 2025-05-31 | Dupixent | $44 |
| Novartis Pharmaceuticals | Meals · 2025-05-30 | None | $48 |
| Genzyme | Meals · 2025-05-30 | Dupixent | $6 |
| Optinose US | Meals · 2025-05-29 | Xhance | $133 |
| Optinose US | Meals · 2025-05-23 | Xhance | $126 |
| Optinose US | Travel · 2025-05-23 | Xhance | $1,310 |
| Optinose US | Paid to speak or teach · 2025-05-23 | Xhance | $3,450 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-05-13 | Dupixent | $2,932 |
| Regeneron Healthcare Solutions | Meals · 2025-05-03 | Dupixent | $119 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-04-15 | Dupixent | $1,350 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-04-15 | None | $1,999 |
| Regeneron Healthcare Solutions | Travel · 2025-04-11 | Dupixent | $228 |
| Optinose US | Paid to speak or teach · 2025-04-08 | Xhance | $1,500 |
| GlaxoSmithKline | Meals · 2025-04-04 | Nucala | $125 |
| Regeneron Healthcare Solutions | Paid to speak or teach · 2025-04-01 | Dupixent | $5,597 |
| Regeneron Healthcare Solutions | Travel · 2025-03-27 | Dupixent | $183 |
| Regeneron Healthcare Solutions | Travel · 2025-03-26 | Dupixent | $207 |
| Regeneron Healthcare Solutions | Travel · 2025-03-20 | Dupixent | $604 |
| Optinose US | Paid to speak or teach · 2025-03-19 | Xhance | $920 |
| Genentech USA | Meals · 2025-03-19 | Xolair | $143 |
| Regeneron Healthcare Solutions | Meals · 2025-03-07 | Dupixent | $125 |
| Genzyme | Meals · 2025-03-02 | Dupixent | $61 |
| Genzyme | Meals · 2025-03-02 | Dupixent | $61 |
| Genzyme | Paid to speak or teach · 2025-03-02 | Dupixent | $2,752 |
| Greer Laboratories | Meals · 2025-03-02 | Palforzia | $52 |
| ALK-Abello | Meals · 2025-03-01 | None | $82 |
| Genzyme | Meals · 2025-03-01 | Dupixent | $39 |
| ALK-Abello | Meals · 2025-02-28 | Odactra | $74 |
| Optinose US | Meals · 2025-02-21 | Xhance | $44 |
| Optinose US | Travel · 2025-02-21 | Xhance | $13 |
| Optinose US | Paid to speak or teach · 2025-02-21 | Xhance | $1,495 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Dupixent | $319 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Dupixent | $89 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Dupixent | $153 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Dupixent | $50 |
| Regeneron Healthcare Solutions | Meals · 2025-02-11 | Dupixent | $19 |
| Regeneron Healthcare Solutions | Meals · 2025-02-11 | Dupixent | $23 |
| Regeneron Healthcare Solutions | Travel · 2025-02-11 | Dupixent | $11 |
| Optinose US | Meals · 2025-01-29 | Xhance | $125 |
| Optinose US | Meals · 2025-01-29 | Xhance | $26 |
| Optinose US | Travel · 2025-01-29 | Xhance | $875 |
| Optinose US | Paid to speak or teach · 2025-01-29 | Xhance | $2,530 |
| kaleo | Meals · 2025-01-23 | Auvi-Q | $92 |
| ALK-Abello | Honoraria · 2025-01-22 | None | $1,800 |
| kaleo | Consulting · 2025-01-22 | Auvi-Q | $1,000 |
| Regeneron Healthcare Solutions | Meals · 2025-01-10 | Dupixent | $70 |
| ALK-Abello | Meals · 2025-01-09 | None | $114 |
| kaleo | Paid to speak or teach · 2025-01-09 | Auvi-Q | $1,500 |
| kaleo | Consulting · 2025-01-08 | Auvi-Q | $1,000 |
| kaleo | Travel · 2025-01-08 | Auvi-Q | $301 |
| kaleo | Travel · 2025-01-08 | Auvi-Q | $571 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $82,688
| Genzyme | Dupixent | $42,496 | 47 payments
|
| Optinose US | Xhance | $20,563 | 23 payments
|
| Regeneron Healthcare Solutions | Dupixent | $13,474 | 19 payments
|
| Grifols USA | Xembify | $2,863 | 4 payments
|
| Novartis Pharmaceuticals | None | $2,276 | 4 payments
|
| GlaxoSmithKline | Nucala | $198 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $180 | 3 payments
|
| Blueprint Medicines | None | $173 | 2 payments
|
| Abbvie | Rinvoq | $172 | 3 payments
|
| Dermavant Sciences | Vtama | $89 | 1 payment
|
| CSL Behring | Haegarda | $81 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Cuvitru | $34 | 1 payment
|
| ALK-Abello | Odactra | $29 | 1 payment
|
| Incyte | Opzelura | $24 | 1 payment
|
| Genentech USA | Xolair | $21 | 1 payment
|
| kaleo | Auvi-Q | $15 | 1 payment
|
2023: $57,119
| Genzyme | Dupixent | $19,746 | 44 payments
|
| Regeneron Healthcare Solutions | Dupixent | $17,062 | 39 payments
|
| Optinose US | Xhance | $9,415 | 20 payments
|
| Novartis Pharmaceuticals | Xolair | $4,492 | 7 payments
|
| AbbVie | Rinvoq | $2,719 | 6 payments
|
| Blueprint Medicines | Ayvakit | $2,134 | 9 payments
|
| BioCryst US Sales Co. | Orladeyo | $453 | 5 payments
|
| ALK-Abello | Grastek | $314 | 10 payments
|
| Pfizer | Cibinqo | $237 | 5 payments
|
| GlaxoSmithKline | Nucala | $195 | 7 payments
|
| Dermavant Sciences | Vtama | $130 | 1 payment
|
| ADMA BioManufacturing | None | $90 | 2 payments
|
| kaleo | Auvi-Q | $51 | 3 payments
|
| Genentech USA | Xolair | $38 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Takhzyro | $18 | 1 payment
|
2022: $36,869
| OptiNose US | Xhance | $29,369 | 46 payments
|
| ALK-Abello | Odactra | $5,874 | 23 payments
|
| Genzyme | Dupixent | $587 | 15 payments
|
| Regeneron Healthcare Solutions | Dupixent | $257 | 10 payments
|
| Pfizer | Cibinqo | $229 | 6 payments
|
| GlaxoSmithKline | Nucala | $221 | 7 payments
|
| kaleo | Auvi-Q | $80 | 3 payments
|
| BioCryst US Sales Co. | Orladeyo | $64 | 2 payments
|
| Amgen | Tezspire | $53 | 2 payments
|
| Aimmune Therapeutics | Palforzia | $52 | 1 payment
|
| Incyte | Opzelura | $51 | 3 payments
|
| Teva Pharmaceuticals USA | None | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $15 | 1 payment
|
2021: $26,512
| ALK-Abello | Odactra | $14,579 | 31 payments
|
| GlaxoSmithKline | Nucala | $7,264 | 13 payments
|
| Optinose US | Xhance | $3,951 | 9 payments
|
| Genzyme | Dupixent | $193 | 5 payments
|
| Regeneron Healthcare Solutions | Dupixent | $190 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | None | $139 | 2 payments
|
| kaleo | Auvi-Q | $71 | 4 payments
|
| Pfizer | Eucrisa | $38 | 2 payments
|
| Aimmune Therapeutics | Palforzia | $36 | 2 payments
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $20 | 1 payment
|
| Amgen | None | $17 | 1 payment
|
| Genentech USA | Xolair | $14 | 1 payment
|
2020: $24,608
| OptiNose US | Xhance | $13,308 | 33 payments
|
| GlaxoSmithKline | Nucala | $7,988 | 8 payments
|
| ALK-Abello | Odactra | $3,044 | 9 payments
|
| Genzyme | Dupixent | $88 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $61 | 4 payments
|
| kaleo | Auvi-Q | $35 | 2 payments
|
| Pfizer | Eucrisa | $33 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $27 | 1 payment
|
| Sanofi-Aventis U.S. | Dupixent | $24 | 1 payment
|
2019: $20,458
| ALK-Abello | Odactra | $14,575 | 17 payments
|
| OptiNose US | Xhance | $5,129 | 16 payments
|
| GlaxoSmithKline | Nucala | $231 | 7 payments
|
| Regeneron Healthcare Solutions | Dupixent | $168 | 11 payments
|
| Kaleo | Auvi-Q | $115 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $91 | 6 payments
|
| Pfizer | Eucrisa | $78 | 5 payments
|
| Genzyme | Dupixent | $47 | 3 payments
|
| Genentech USA | Xolair | $25 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| GENZYME CORPORATION · A Randomized, Double-Blind, Head-To-Head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (Crswnp) and Comorbid Asthma Patients · 2024 | Their institution | $14,700 |
Professional record
- NPI
- 1700815677
- Licence
- DC 036032, VA 0101239697
- Group
- Allergy and Asthma Medical Group of the Bay Area Inc · Johns Hopkins University
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0201X (207RA0201X); Federal specialty code 207KA0200X (207KA0200X); Federal specialty code 2080P0201X (2080P0201X)
- Mailing address
- 370 N. Widget Lane, Suite 210, Walnut Creek, CA, 94598
- NPI first listed
- 2006-07-02
- NPI last updated
- 2026-07-31
- NPI record certified
- 2026-07-31
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1715 N George Mason Dr, Arlington, VA, 22205 · 1800 Orleans St, Baltimore, MD, 21287